Walgreens Concludes Public Market Era with Landmark Private Equity Acquisition

In a move that ends its nearly century-long presence on public markets, Walgreens Boots Alliance has been formally acquired by private equity firm Sycamore Partners. The $10 billion deal, finalized on Wednesday, triggers the immediate breakup of the pharmacy giant into five distinct, privately-held companies.

A New Leadership Team Takes Command

The acquisition precipitated a complete overhaul of the company’s executive leadership. Mike Motz, the former chief executive of Staples, has been named the new CEO of Walgreens. Motz brings extensive retail expertise to the role, including prior experience leading Shoppers Drug Mart, Canada’s premier pharmacy chain.

This appointment signals a strategic refocus on core operations, reversing years of unsuccessful diversification efforts. Tim Wentworth, who had been steering turnaround initiatives since 2023, has stepped down from the CEO position but will remain on the board of directors.

The new leadership is rounded out by John Lederer, a former WBA director and current senior advisor at Sycamore Partners, who assumes the role of Executive Chairman.

An Unprecedented Corporate Breakup

The transaction has set in motion a radical corporate dissolution. Walgreens Boots Alliance is being split into the following five independent entities:

• Walgreens – The core US pharmacy retail business
• The Boots Group – Its international pharmacy operations
• Shields Health Solutions – A provider of specialty pharmacy services
• CareCentrix – A home healthcare services company
• VillageMD – A primary care clinic network

This strategy is designed to allow each business unit to operate autonomously under private ownership, free from the quarterly earnings pressures of the public equity markets.

Final Payout for Shareholders

As part of the deal, shareholders received a cash payment of $11.45 per share. Additionally, they are entitled to non-transferable rights to a portion of future VillageMD proceeds, which could amount to an extra $3 per share paid out over a four-year period.

A critical caveat exists: these contingent payments are capped at 70% of the net proceeds from any future sales of VillageMD.

Should investors sell immediately? Or is it worth buying Walgreens?

Closing the Book on a Public Listing

Trading in WBA shares was halted following Wednesday’s market session. The stock concluded its final day of trading at $11.98, marking a 28% gain since the start of the year despite the company’s well-documented operational challenges.

The delisting removes Walgreens from all major stock indices, where it had been a mainstay for decades.

Drivers Behind the Drastic Move

The decision to go private follows a period of significant struggle for the company. Walgreens had been contending with declining retail sales, contracting pharmacy margins, and soaring losses from inventory theft. Its ambitious foray into healthcare through the VillageMD clinic network failed to yield profits, resulting instead in clinic closures and multimillion-dollar losses.

Recent financial results highlight these difficulties: a $175 million net loss was reported for the latest third quarter, a stark reversal from the $344 million profit recorded in the same period a year earlier. Faced with over $7 billion in long-term debt, a private equity exit emerged as a viable strategic alternative.

Sector-Wide Shifts Fuel Consolidation

This acquisition reflects the broader transformation occurring within the pharmacy and retail healthcare sector. Intense competition from giants like Amazon and Walmart is increasing pressure, while models for healthcare delivery are undergoing radical change.

Operating privately affords the newly separated companies greater flexibility to shutter unprofitable locations, invest in digital transformation, and restructure—all without the scrutiny of public market investors. Plans are already underway to close 1,200 of its 8,500 US stores.

This transaction may serve as a blueprint for further private equity acquisitions within the beleaguered pharmacy retail industry.